Why an Expired HSR Waiting Period Is Not a Safe Harbor
The HSR issue in CareFirst v. Amgen is precise: what does it mean that the 2004 Amgen–Roche restructuring received early termination of the Hart-Scott-Rodino waiting period? It means something about when the agencies would act during a statutory review window. It does not, by itself, decide whether the completed transaction later functioned as exclusionary conduct. Keeping those questions separate lets the reader interpret the HSR event accurately and understand why a later Section 2 inquiry is not a contradiction.
What the HSR waiting period is designed to do
The Hart-Scott-Rodino Act requires advance notice of qualifying mergers and acquisitions. The notice and waiting period give the Federal Trade Commission and the Department of Justice an opportunity to consider a transaction before it proceeds without delay. The FTC’s amicus brief describes this as a pre-consummation process for large mergers and acquisitions. The important feature is timing: HSR operates around the point at which a deal is proposed and before the parties complete it.
That timing creates a limited question. During the waiting period, will either agency take action that requires the transaction to be held for further consideration? If the waiting period ends early, the parties are no longer waiting under that statutory process. Early termination is therefore a procedural event. It changes the parties’ ability to move forward under the waiting-period rule; it does not pronounce on every legal consequence the transaction might have later.
The FTC’s brief quotes 15 U.S.C. § 18a(b)(2) for the meaning it assigns to the agencies’ decision. If neither the FTC nor DOJ intends to take action during the waiting period, early termination does not determine the transaction’s legality, endorse it, or preclude later antitrust scrutiny. Those three limits are the core of the case’s HSR lesson.
The first limit is legality. Early termination is not a judgment that the transaction satisfies all antitrust standards. An HSR decision occurs in a particular procedural setting and time window. A later claim may examine how the completed transaction operated in a defined market, what rights it transferred, and whether it acquired or maintained monopoly power through exclusionary conduct. Those questions are not answered merely because the waiting period ended.
The second limit is endorsement. The absence of agency action during the waiting period is not an affirmative statement that the agencies approve the transaction’s competitive effects. It does not convert the agencies into guarantors of the deal’s future consequences. In the CareFirst account, the fact that the restructuring received early termination can coexist with a later dispute about whether exclusive control of pending patent applications prolonged Enbrel exclusivity.
The third limit is later scrutiny. Ending the waiting period does not prevent another antitrust inquiry from examining the transaction. The FTC’s brief expressly points to later scrutiny as compatible with early termination. A private plaintiff may allege that a completed deal violated Section 2, and a court may assess that theory, without treating the earlier HSR event as meaningless or overruling it. The events answer different questions.